血液及血液成分市场机会、成长要素、产业趋势分析及预测（2026-2035年）

全球血液和血液成分市场预计到 2025 年将达到 142 亿美元，到 2035 年将达到 207 亿美元，年复合成长率为 4%。

由于全球外科手术数量不断增加、慢性疾病盛行率上升以及血浆疗法在各种临床环境中的广泛应用，市场正经历稳定成长。血液采集机构持续进行的宣传活动和捐血宣传活动，为稳定的血液供应提供了保障。血液和血液成分在现代医疗保健系统中仍然至关重要，确保了输血治疗所需的红血球、血浆和血小板的持续供应。这些产品广泛应用于包括急救、外科手术、肿瘤治疗以及血液相关疾病的长期管理等许多领域。市场在严格的品质和安全标准下运作，以确保产品完整性和病人安全。血液采集方法、成分分离、检测、储存和物流方面的持续创新，提高了效率，并满足了全球医疗保健系统日益增长的需求。该行业不断发展，重点关注可靠性、可追溯性和合规性。

预计到2025年，血液成分业务的收入将达到88亿美元。该业务包括红血球、血浆、血小板和白血球，每种成分都发挥特定的治疗作用。由于红血球在恢復低血红蛋白患者的氧气输送方面发挥着至关重要的作用，因此其需求量仍然很高。全球血液相关疾病的负担持续沉重，推动了基于血液成分治疗方法的长期应用，使该业务成为核心收入来源。

预计2025年，医院将占血液及血液成分消费总量的72%。医疗机构在急诊护理、外科手术、肿瘤治疗和慢性病治疗中发挥核心作用，因此仍是血液及血液成分的主要消费群体。复杂医疗干预的增加、创伤病例的增多以及先进治疗通讯协定的广泛应用，共同推动了医院对血液及血液成分的持续稳定需求，巩固了其作为终端用户的主导地位。

预计2025年，北美血液及血液成分市占率将达到39.8%。该地区受益于完善的医疗保健基础设施、较高的捐血参与率以及输血疗法在各种临床应用中的积极使用。先进的医疗实践、高效的血液管理系统和健全的製度框架持续巩固该地区的市场主导地位。

目录

第一章调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 产业影响因素
  • 司机
    • 全球手术数量不断增加。
    • 患有慢性疾病（包括癌症）的人数不断增加。
    • 扩大血浆疗法在治疗各种运动伤害、整形手术和整形外科手术的应用
    • 多个血液组织宣传活动了多次捐血活动
  • 产业面临的潜在风险与挑战：
    • 血液成分的保存期限短
    • 与捐血相关的输血传染感染（TTI）
  • 市场机会
    • 个人化和标靶治疗的发展
    • 整合数位化解决方案
• 成长潜力分析
• 监管环境
• 技术进步
  • 当前技术趋势
  • 新兴技术
• 供应链分析
• 未来市场趋势
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 公司市占率分析
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 重大进展
  • 併购
  • 合作伙伴关係和合资企业
  • 新产品发布
  • 扩张计划

第五章 2022-2035年按产品分類的市场估算与预测

• 全血
• 血液成分
  • 红血球
  • 血小板
  • 电浆
  • 白血球

第六章 按应用领域分類的市场估算与预测，2022-2035年

• 创伤及外科手术
• 血液疾病
  • 贫血
  • 出血性疾病
    • 血友病
    • 血管性血友病
  • 其他血液疾病
• 癌症治疗
• 其他用途

7. 依最终用途分類的市场估计与预测，2022-2035 年

• 医院
• 门诊手术中心
• 其他用途

第八章 2022-2035年各地区市场估算与预测

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿拉伯聯合大公国

第九章：公司简介

• American Red Cross
• America's Blood Centers
• Associazione Volontari Italiani del Sangue（AVIS）
• Bloodworks Northwest
• Canada Blood Services
• Carter BloodCare
• ImpactLife
• Indian Red Cross Society
• NHS Blood and Transplant（NHSBT）
• Northern Ireland Blood Transfusion Service
• OneBlood
• Scottish National Blood Transfusion Service（NHS National Services Scotland）
• Versiti
• Vitalant
• Welsh blood service

The Global Blood and Blood Components Market was valued at USD 14.2 billion in 2025 and is estimated to grow at a CAGR of 4% to reach USD 20.7 billion by 2035.

The market is experiencing steady growth due to the rising number of surgical procedures worldwide, the increasing prevalence of long-term medical conditions, and the expanding use of plasma-based therapies across a wide range of clinical treatments. Continuous awareness initiatives and donation drives conducted by blood collection organizations are supporting a stable supply pipeline. Blood and blood components remain essential to modern healthcare systems, as they ensure uninterrupted access to red blood cells, plasma, and platelets required for transfusion-based therapies. These products are widely used across emergency care, surgical interventions, oncology treatments, and the long-term management of blood-related disorders. The market operates under strict quality and safety frameworks to maintain product integrity and patient safety. Ongoing innovation in blood collection methods, component separation, testing, storage, and logistics is improving efficiency and meeting the rising demands of global healthcare systems. The industry continues to evolve with a strong focus on reliability, traceability, and regulatory compliance.

The blood components segment generated USD 8.8 billion in 2025. This segment includes red blood cells, plasma, platelets, and white blood cells, each fulfilling specialized therapeutic roles. Red blood cells remain in high demand due to their essential function in restoring oxygen delivery in patients with reduced hemoglobin levels. The global burden of blood-related conditions continues to support sustained utilization of component-based therapies, making this segment a core revenue contributor.

The hospitals segment accounted for 72% share in 2025. Healthcare facilities remain the primary consumers of blood and blood components due to their central role in managing emergency care, surgical procedures, oncology services, and chronic disease treatment. The growing volume of complex medical interventions, combined with increasing trauma cases and advanced treatment protocols, continues to drive consistent demand from hospitals, reinforcing their dominance as end users.

North America Blood and Blood Components Market held a 39.8% share in 2025. The region benefits from a well-established healthcare infrastructure, strong donor participation, and high utilization of transfusion therapies across multiple clinical applications. Advanced medical practices, efficient blood management systems, and strong institutional frameworks continue to support regional market leadership.

Key organizations operating in the Global Blood and Blood Components Market include Vitalant, Canada Blood Services, American Red Cross, OneBlood, NHS Blood and Transplant, ImpactLife, America's Blood Centers, Versiti, Bloodworks Northwest, Carter BloodCare, Indian Red Cross Society, Associazione Volontari Italiani del Sangue, Northern Ireland Blood Transfusion Service, Scottish National Blood Transfusion Service, and the Welsh Blood Service. Companies in the blood and blood components market are strengthening their market position by expanding donor networks, improving collection efficiency, and investing in advanced processing and storage technologies. Organizations are focusing on digital donor engagement platforms to improve donor retention and streamline appointment scheduling. Strategic collaborations with hospitals and healthcare systems are enhancing supply reliability and demand forecasting.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Application trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing volume of surgeries globally
    • 3.2.1.2 Rising number of people suffering from chronic conditions including cancer
    • 3.2.1.3 Growing popularity of plasma therapy to treat various sport injuries, cosmetic as well as orthopedic procedures
    • 3.2.1.4 Several blood donation campaigns undertaken by various blood organizations
  • 3.2.2 Industry Pitfalls and Challenges:
    • 3.2.2.1 Short shelf life of blood components
    • 3.2.2.2 Transfusion transmitted infection (TTI) related to donated blood
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Growth in personalized and targeted therapies
    • 3.2.3.2 Integration of digital solutions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Supply chain analysis
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Whole blood
• 5.3 Blood components
  • 5.3.1 Red blood cells
  • 5.3.2 Platelets
  • 5.3.3 Plasma
  • 5.3.4 White blood cells

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Trauma and Surgery
• 6.3 Blood disorders
  • 6.3.1 Anaemia
  • 6.3.2 Bleeding disorders
    • 6.3.2.1 Hemophilia
    • 6.3.2.2 Von willebrand disease
  • 6.3.3 Other blood disorders
• 6.4 Cancer treatment
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 American Red Cross
• 9.2 America's Blood Centers
• 9.3 Associazione Volontari Italiani del Sangue (AVIS)
• 9.4 Bloodworks Northwest
• 9.5 Canada Blood Services
• 9.6 Carter BloodCare
• 9.7 ImpactLife
• 9.8 Indian Red Cross Society
• 9.9 NHS Blood and Transplant (NHSBT)
• 9.10 Northern Ireland Blood Transfusion Service
• 9.11 OneBlood
• 9.12 Scottish National Blood Transfusion Service (NHS National Services Scotland)
• 9.13 Versiti
• 9.14 Vitalant
• 9.15 Welsh blood service